Visus Therapeutics to Present at the Baird 2022 Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Visus Therapeutics, Inc. (“Visus”), a clinical stage biopharmaceutical company focused on treating complex and multifactorial conditions from the front to the back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13^th, 2022, at the InterContinental New York Barclay hotel.

The presentation is scheduled for 12:50 PM Eastern Time on Tuesday, September 13^th. Mr. Bergo will also be available for one-on-one investor meetings on Tuesday, September 13^th.

The company presentation will be available on Visus' website at https://www.visustx.com/news.

About Visus Therapeutics

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on treating complex and multifactorial conditions from the front to the back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter, and Instagram.